Mr. Richard Lee Shobe, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1755 Ivy St, Junction City, OR 97448 Phone: 541-998-4526 |
Megan Joaquin, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1755 Ivy St, Junction City, OR 97448 Phone: 541-998-4526 |
Dr. Abigail Larson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 110 E 6th Ave, Junction City, OR 97448 Phone: 541-998-6498 |
Anh Vu Vuong, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 29398 Recovery Way, Junction City, OR 97448 Phone: 541-465-2646 Fax: 541-465-2647 |
Dr. Randall Rohaul Skirvin, D.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 110 E 6th Ave, Junction City, OR 97448 Phone: 541-998-6498 Fax: 541-998-6693 |
Amanda Cuillier, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1755 Ivy St, Junction City, OR 97448 Phone: 541-998-4526 Fax: 541-998-4528 |
Jennifer Johnson Gardner, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 23988 Highway 99 W, Junction City, OR 97448 Phone: 541-510-4158 |
News Archive
NYU School of Medicine announced the creation of a new Department of Population Health focused on research to improve human health at the population level. Marc Gourevitch, MD, MPH, professor of population health and medicine at NYU School of Medicine was appointed inaugural chair.
Americans' confidence in medical scientists has grown since the coronavirus outbreak first began to upend life in the United States, as have perceptions that medical doctors hold very high ethical standards, according to a new Pew Research Center report.
Researchers of the Fraunhofer Institute for Molecular Biology and Applied Ecology IME have developed software for Germany that calculates the concentration of pesticides/plant protection products in surface waters like ditches or streams. The new process can be employed as a component of pesticide authorization procedures.
Icagen, Inc. today announced that, following a review of data from recently completed clinical studies as well as the Company's proposed protocol for a Phase II clinical trial in patients with treatment resistant epilepsy, the FDA has notified the Company that the clinical hold on Icagen's IND for ICA-105665, a novel orally available small molecule KCNQ potassium channel agonist, has been removed.
› Verified 5 days ago